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Introduction: Lymphoepitheliomas are malignant epithelial tumors of the nasopharynx characterized by an
important lymphoid proliferation at histological examination. Lymphoepithelioma-like carcinoma is a rare tumor of
the bladder for which the therapeutic strategy is not clearly defined.
Case presentation: We report the case of a 64-year-old Moroccan man who presented with macroscopic
hematuria. Investigations revealed a muscle-invasive lymphoepithelioma-like carcinoma of the bladder. Therefore he
underwent a radical cystoprostatectomy with a good outcome.
Conclusion: This case illustrates pathogenic, clinical and therapeutic features of this unusual tumor.
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Lymphoepitheliomas are undifferentiated malignant epi-
thelial tumors of the nasopharynx which are recognized
histologically by lymphocytic infiltration suggesting an
important malignant lymphoma. Tumors of similar
histological type have been described in other sites out-
side of the nasopharynx (lung, stomach, cervix, skin)
and are known as lymphoepithelioma-like carcinomas
(LELC). The primary urothelial LELC was described for
the first time by Zukerberg et al. in 1991 [1]. The LELC
is a tumor that rarely reaches the urinary tract: there
were only 80 cases reported in the bladder, 10 cases in
the ureter, and 7 cases in the renal pelvis [2].
We report the case of a patient who had a muscle-
invasive LELC of the bladder, and review the literature
on this rare condition in order to clarify the clinical and
therapeutic features.Case presentation
A 64-year-old Moroccan man had a history of chronic
smoking and arterial hypertension treated by losartan
and hydrochlorothiazide. He reported a hematuria 2
months ago with blood clots in his urine. His physical
examination was normal. Ultrasounds revealed an* Correspondence: imad.ziouziou@um5s.net.ma
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unless otherwise stated.intravesical echogenic image localized at the left-side wall
of his bladder measuring 22mm×26mm (Figure 1).
Cystoscopic exploration revealed a solid lesion in the left
wall with a large base. A transurethral resection of the
bladder tumor was performed. A pathological examination
revealed a proliferation of cells with large vesicular nuclei,
nucleoli and high mitotic activity. These cells were either
arranged in syncytial clusters or isolated within a pre-
dominant lymphoid stroma. This proliferation infiltrated
(Figures 2, 3 and 4) muscle. An immunohistochemical
examination (cytokeratin positivity) confirmed the diagno-
sis of LELC of the bladder (Figure 5).
Chest and abdominopelvic computed tomography
(CT) did not show pelvic lymphadenopathy or secondary
location. A radical surgery was then decided without
neoadjuvant therapy.
Cystoprostatectomy with Bricker diversion and lymph
node dissection were performed. The postoperative
course was uneventful.
The pathological examination of the surgical specimen
revealed no residual tumor lesion and non-invaded lymph
nodes (T0 N0).
After 12 months, the patient was in good condition with
normal renal function, and normal chest-abdominopelvic
CTs at 6 and 12 months.al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Echogenic ultrasound image at the left wall of
the bladder.
Figure 3 Syncytial clusters of undifferentiated highly vesicular
nucleolus nucleus (arrows) cells bathed in abundant lymphoid
stroma (*): hematein and eosin ×200.
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LELC of the bladder were classified as a distinct variant of
urothelial carcinomas in the classification of the World
Health Organization of urothelial tumors in 2004 [3].
The lymphoepithelial carcinoma of the nasopharynx is
strongly associated with infection with the Epstein–Barr
virus (EBV). However, no risk factor is known for LELC
of the bladder [4]; the average age of patients was 65
years with a sex ratio (M:F) of 2:5 [4].
Gulley et al. looked for the presence of EBV in LELC
of the bladder by in situ hybridization techniques: none
of 11 cases had viral DNA [5].
Two cases of post-Bacillus Calmette–Guérin (BCG)
therapy LELC have been reported by Gastaud et al. and
Izquierdo-Garcia et al., suggesting a role of immune
system activation after the BCG therapy [6,7].
The clinical presentation of LELC of the bladder does
not differ from that of urothelial carcinomas. It isFigure 2 Massive tumoral infiltration of the stroma with regular
superficial urothelial mucosa: hematein and eosin ×200.dominated by macroscopic hematuria and irritative
voiding disorders.
At endoscopy, the tumor is often unifocal, small, and
has a polypoid form [1,2]. Our case had the same clinical
and endoscopic characteristics described in the literature.
LELC is characterized in its pure form by an undiffer-
entiated epithelial tumor with a significant lymphocytic
infiltration [8].
Amin et al. subdivided LELC – depending on the im-
portance of urothelial carcinoma within the tumor – into
[8]: pure LELC, predominant LELC (lymphoepithelial
component greater than 50%), and focal LELC (lymphoe-
pithelial component less than 50%).
The predominance of lymphoepithelial component is a
good prognostic factor. For some authors, conservative
treatment can be achieved even in invasive forms because
of their chemosensitivity. Conservative treatment wasFigure 4 Massive infiltration of muscle (arrows): hematein and
eosin ×200.
Figure 5 Anti-cytokeratin antibody (AE1/AE3): positivity on the
coating surface (an arrow), less positivity on the tumor cells
(two arrows).
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by adjuvant chemotherapy with cisplatin. Progression-free
survival was 47 months as reported by Amin et al. [8]. But
in this series including 11 patients, only one patient had a
predominant LELC form that had chemotherapy with
transurethral resection [8]. The number of cases reported
and managed by conservative treatment is very low. Most
authors recommend radical cystectomy in the case of
muscle infiltration [9].
The pathological form of our case was mixed type, in
which two components coexisted: lymphoepithelial which
was predominant and urothelial.
We opt for radical treatment in patients with urothe-
lial tumor infiltrating the muscle T2 with lymphoepithe-
lial component taking into account the low level of
evidence advocating conservative treatment.
Our patient did not have chemotherapy neither neoad-
juvant nor adjuvant.
Serrano et al. [4] reported a recurrence-free survival in
87.5% of patients who had a pure form and stages T2 or
T3. The prognosis of pure forms is linked to the import-
ance of the inflammatory infiltrate and cytotoxic T lym-
phocytes for two reasons: early onset of symptoms causing
patients to seek care, and strengthening the action of sub-
stances used in chemotherapy [4].
Most authors advocate the quasi-systematic use of
cisplatin-based chemotherapy as adjuvant treatment
after transurethral resection or cystectomy [10]. There
are even some that offer BCG therapy [11].
Conclusions
LELC is a rare tumor of the bladder with no therapeutic
consensus. Radical treatment seems most appropriate for
muscle invasive urothelial tumors with LELC component,especially as literature data, advocating conservative treat-
ment regardless of the tumor stage, has a low level of
evidence.
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